LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway.
Gao A, Sun T, Ma G, Cao J, Hu Q, Chen L, Wang Y, Wang Q, Sun J, Wu R, Wu Q, Zhou J, Liu L, Hu J, Dong JT, Zhu Z.
Gao A, et al. Among authors: cao j.
Nat Commun. 2018 Oct 9;9(1):4180. doi: 10.1038/s41467-018-06309-8.
Nat Commun. 2018.
PMID: 30301939
Free PMC article.